We will know a lot more about the vaccine maker's long-term prospects in 12 months.What a difference a few months make. Vaccine specialist Novavax (NVAX -1.32%) started the year poorly, continuing with the issues it has encountered since mid-2021.Those headwinds included the difficulties it faced in launching its COVID vaccine in the U.S. and the significant slowdown in demand for these products, leading to a decline in revenue and earnings for the biotech.However, several developments have jolted Novavax's ...